1. Home
  2. PLRX
  3. PLRX Forecast

as of 04-20-2026 3:40pm EST

$1.29
$0.04
-3.01%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.

Frequently Asked Questions

Learn more about our PLRX ML prediction model

What parameters are used to train the PLRX ML model?

Our stocks PLRX ML model is trained using historical data with over 25 parameters, including volume indicators, volatility indicators, momentum indicators, trend indicators, and other technical metrics.

How often is the PLRX ML model updated?

We update our ML model weekly or biweekly (depending on market capitalization) using TensorFlow, typically over the weekend to ensure the most current predictions.

Why might the model accuracy vary?

Our current data provider offers limited historical data, which can impact accuracy. As we continue to gather more data and add additional indicators, we expect the model's accuracy to improve over time.

How can I contribute data to improve accuracy?

We greatly appreciate contributions! Please contact us at info@finquota.com to discuss how you can help improve our models.

Are shorter timeframe predictions available?

Yes, we offer predictions for strategy purposes with shorter intervals including 1 minute, 2 minutes, 5 minutes, 15 minutes, and 30 minutes timeframes.

Should I use this for financial decisions?

Our ML model is designed for educational purposes only and should not be used as the sole basis for financial decisions. Always consult with a qualified financial advisor before making any investment decisions.

Share on Social Networks: